Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor (ab141083)
Key features and details
- Potent HMG-CoA reductase inhibitor
- CAS Number: 134523-03-8
- Purity: > 99%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor -
Description
Potent HMG-CoA reductase inhibitor -
Purity
> 99% -
CAS Number
134523-03-8 -
Chemical structure
Properties
-
Chemical name
(βR,δR)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt -
Molecular weight
577.68 -
Molecular formula
C33H34FN2O5.0.5Ca -
PubChem identifier
60822 -
Storage instructions
Store at -20°C. It is important to note that this product is reported to be light sensitive. Store In the Dark. Store under desiccating conditions. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
[Ca+2].O[C@H](CCn1c(c(c(c1C(C)C)C(=O)Nc2ccccc2)c3ccccc3)c4ccc(F)cc4)C[C@@H](O)CC([O-])=O.[O-]C(=O)C[C@H](O)C[C@H](O)CCn4c(c1ccc(F)cc1)c(c2ccccc2)c(C(=O)Nc3ccccc3)c4C(C)C -
Source
Synthetic
-
Research areas
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
- Orphan Nuclear Receptors
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Nucleotide metabolism
- Molecular processes
- Mitochondrial transcription
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab141083 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
Notes |
---|
Functional Studies
Use at an assay dependent concentration. |
Images
-
2D chemical structure image of ab141083, Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor
-
ab90529 staining cytochrome C in HepG2 cells treated with atorvastatin hemicalcium salt (ab141083), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of atorvastatin hemicalcium salt, as described in literature.
The cells were incubated at 37°C for 4 hours in media containing different concentrations of ab141083 (atorvastatin hemicalcium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (0)
ab141083 has not yet been referenced specifically in any publications.